Indoco Remedies Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is BRINZOLAMIDE USP, with a corresponding US DMF Number 28134.
Remarkably, this DMF maintains an Active status since its submission on April 02, 2014, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of August 24, 2015, and payment made on May 15, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II